MedTrace Logo

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

NCT04679870 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2024-04-03

No results posted yet for this study

Summary

This study is an open label, phase IIa trial in subjects with Myelofibrosis

Conditions

Interventions

DRUG

GB2064

GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day

Sponsors & Collaborators

  • OPIS s.r.l

    collaborator UNKNOWN

  • Galecto Biotech AB

    lead INDUSTRY

Principal Investigators

  • Richard F Schlenk, MD · Universitätsklinikum Heidelberg, Germany

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-09
Primary Completion
2023-12-31
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Germany
  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04679870 on ClinicalTrials.gov